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ORIGINAL ARTICLE
The atypical chemokine receptor ACKR2 suppresses
Th17 responses to protein autoantigens
Chris AH Hansell, Lindsay M MacLellan, Rachel S Oldham, James Doonan, Katie J Chapple,
Elinor JR Anderson, Christopher Linington, Iain B McInnes, Robert JB Nibbs1 and Carl S Goodyear1
Chemokine-directed leukocyte migration is a critical component of all innate and adaptive immune responses. The atypical
chemokine receptor ACKR2 is expressed by lymphatic endothelial cells and scavenges pro-inﬂammatory CC chemokines to
indirectly subdue leukocyte migration. This contributes to the resolution of acute inﬂammatory responses in vivo. ACKR2 is also
universally expressed by innate-like B cells, suppressing their responsiveness to the non-ACKR2 ligand CXCL13, and controlling
their distribution in vivo. The role of ACKR2 in autoimmunity remains relatively unexplored, although Ackr2 deﬁciency reportedly
lessens the clinical symptoms of experimental autoimmune encephalomyelitis induced by immunization with encephalogenic
peptide (MOG35–55). This was attributed to poor T-cell priming stemming from the defective departure of dendritic cells from the
site of immunization. However, we report here that Ackr2-deﬁcient mice, on two separate genetic backgrounds, are not less
susceptible to autoimmunity induced by immunization, and in some cases develop enhanced clinical symptoms. Moreover,
ACKR2 deﬁciency does not suppress T-cell priming in response to encephalogenic peptide (MOG35–55), and responses to protein
antigen (collagen or MOG1–125) are characterized by elevated interleukin-17 production. Interestingly, after immunization with
protein, but not peptide, antigen, Ackr2 deﬁciency was also associated with an increase in lymph node B cells expressing
granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that enhances T helper type 17 (Th17) cell development
and survival. Thus, Ackr2 deﬁciency does not suppress autoreactive T-cell priming and autoimmune pathology, but can enhance
T-cell polarization toward Th17 cells and increase the abundance of GM-CSF+ B cells in lymph nodes draining the site of
immunization.
Immunology and Cell Biology advance online publication, 28 October 2014; doi:10.1038/icb.2014.90
Chemokines play a major role in orchestrating innate and adaptive
immune responses by controlling the migration of leukocytes using G
protein-coupled chemokine receptors that decorate the surface of
these cells.1 Alongside the large chemokine receptor family is a small
subfamily of ‘atypical’ chemokine receptors, members of which bind
chemokines with high afﬁnity and speciﬁcity but appear incapable of
classical chemokine receptor behavior.2 This subfamily is typiﬁed by
ACKR2 (D6)3 a heptahelical membrane molecule structurally related
to other chemokine receptors that binds a broad array of pro-
inﬂammatory CC chemokines. In humans, ACKR2 is expressed by
lymphatic endothelial cells, trophoblasts and some leukocyte
populations.4–8 In mice, we have recently found that, among
leukocytes, ACKR2 is highly restricted to innate-like B cells (IBCs)
(that is, marginal zone and B1 B cells), and is the best unifying marker
of these cells.9 IBCs serve key roles during homeostasis, autoimmunity
and infection, and new properties of these cells continue to be deﬁned.
For example, recent work has revealed that B1 B cells generate ‘innate
response activator’ B cells during inﬂammation that are dominant
sources of the cytokine granulocyte-macrophage colony-stimulating
factor (GM-CSF) in secondary lymphoid tissue.10
What sets ACKR2 and other atypical chemokine receptors apart is
their inability to couple to signaling pathways activated after classical
chemokine receptor engagement. Neither ACKR2-transfected cell lines
nor primary ACKR2-expressing leukocytes migrate toward ACKR2
ligands.2,9 This, coupled with the ability of ACKR2 to continuously
internalize chemokines,11–15 supports the concept that the principal
function of ACKR2 is to act as a ‘professional’ chemokine scavenger
that indirectly modulates leukocyte migration through chemokine
removal. This model is used to explain phenotypes in challenged
Ackr2-deﬁcient mice that are often characterized by elevated
chemokine abundance, exaggerated inﬂammation and increased
immunopathology.2,5,6,16–21 However, Ackr2 deﬁciency also leads to
cell-autonomous defects among IBCs (for example, increased respon-
siveness to the non-ACKR2 ligand CXCL139) that are not dependent
on loss of chemokine scavenging and could be linked to the ability of
ACKR2 to regulate the subcellular distribution of β-arrestins, key
regulators of G protein-coupled receptors like CXCR5.14,15 B1 cell
distribution in vivo is profoundly dependent on engagement of
CXCR5 by its ligand CXCL13,22 and Ackr2-deﬁcient mice have
fewer B1 B cells in their peritoneal cavity, omentum and spleen than
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wild-type (WT) animals.9 It is not clear whether this is because of the
loss or redistribution of these cells, and the absence of suitable markers
makes it difﬁcult to distinguish B1 B cells from follicular B cells in
other tissues, such as lymph nodes (LNs).
Chemokines are capable of inﬂuencing all the key steps that lead to
the development of pathology in mouse models of autoimmunity,
such as inﬂammation at the site of immunization, delivery of antigen
to draining LNs, development of pathogenic lymphocytes and anti-
bodies and the orchestration of immunopathology in the target
tissue.23,24 Identifying how chemokine receptors contribute to the
induction and maintenance of immunopathology has implications for
the translation of chemokine receptor inhibition to the treatment of
human disease.25 Only one study has examined the impact of Ackr2
deﬁciency in a model of autoimmune disease,26 speciﬁcally experi-
mental autoimmune encephalomyelitis (EAE) induced by immuniza-
tion with a short peptide from rat myelin oligodendrocyte
glycoprotein (MOG), referred to hereafter as MOG35–55. This study
reported that, in contrast to the exaggerated inﬂammation seen in the
absence of Ackr2 in most other models, C57BL/6J Ackr2-deﬁcient mice
developed less brain inﬂammation and clinical symptoms of EAE than
WT counterparts. This was attributed to the suppression of dendritic
cell (DC) migration caused by excessive inﬂammation at the immu-
nization site, and they reported a profound reduction in the
proliferation of LN cells restimulated with MOG35–55 and reduced
interferon-γ (IFNγ) release.26 Indeed, we have subsequently shown
that, during inﬂammation, the absence of Ackr2 is associated with the
deposition of chemokines on skin lymphatic endothelial cells; peri-
lymphatic accumulation of inﬂammatory leukocytes, including DCs;
and concomitant ‘lymphatic congestion’.27
Here, using mice on two different genetic backgrounds, we report a
detailed evaluation of the impact of Ackr2 deﬁciency in four models
of autoimmune disease: collagen-induced arthritis (CIA), collagen
antibody-induced arthritis and EAE induced by immunization with
MOG35–55 peptide or MOG1–125 protein. In none of these models did
the absence of Ackr2 decrease the severity of disease, and in some cases
Ackr2-deﬁcient mice developed worse clinical symptoms than WT
animals. Moreover, T-cell priming was not diminished in Ackr2-
deﬁcient mice, and WT and Ackr2-deﬁcient LN cells had comparable
proliferation when restimulated with antigen. In fact, compared with
WT, cells from the LN of Ackr2-deﬁcient mice draining the site of
immunization with protein (collagen or MOG1–125) but not peptide
(MOG35–55) antigen showed an increased propensity to produce
interleukin-17 (IL-17). Importantly, this was not an intrinsic T-cell
phenomenon as chimeric studies demonstrated that WT and Ackr2-
deﬁcient T cells differentiated equally into T helper type 17 (Th17)
cells when in the same animal. Interestingly, enhanced Th17 responses
were associated with an increase in the abundance of B cells producing
GM-CSF, a cytokine known to enhance Th17 cell development and
survival.28 Thus, in the models we have tested, Ackr2-deﬁcient mice
are not less susceptible to autoimmunity and do not show suppressed
T-cell responses, but can develop enhanced Th17 responses and
greater numbers of GM-CSF+ B cells after immunization with protein
autoantigen.
RESULTS
Ackr2 is upregulated in arthritic mouse joints and suppresses the
severity of CIA in DBA1/j mice
By comparing healthy and arthritic knees from WT DBA1/j mice, we
found that Ackr2 transcripts were signiﬁcantly upregulated in the
target tissue of inﬂammatory arthritis (Figure 1a). We considered
whether loss of the anti-inﬂammatory activity of ACKR2 at this site
might have a more pronounced effect on the development of
autoimmune disease than it is reported to have in the brain.26 To
explore this, we backcrossed Ackr2-deﬁcient C57BL/6J mice onto
DBA/1j and monitored development of arthritis in a large cohort of
animals after immunization with bovine type II collagen, using WT
DBA1/j littermate mice as controls. In contrast to previous observa-
tions in the EAE model,26 the absence of Ackr2 resulted in a
statistically signiﬁcant increase in the clinical symptoms of arthritis
(Figure 1b), and a substantial increase (Po0.05) in the cumulative
clinical score of Ackr2-deﬁcient mice (24.2± 3.6, mean± s.d.) com-
pared with WT mice (13.7± 2.6). There was, however, no change in
the time at which these animals ﬁrst developed symptoms (incidence
of disease) (data not shown). Ackr2-deﬁcient mice often have elevated
levels of ACKR2-binding chemokines in inﬂamed tissues.16,17,20
Consistent with this, two- to threefold more ACKR2-binding chemo-
kines CCL2, CCL3 and CCL4, but not non-ACKR2-binding chemo-
kine CXCL10, were released from explants of patella and adjacent
synovial tissue from arthritic Ackr2-deﬁcient mice, compared with
equivalent preparations from arthritic WT animals (Figure 1c).
Furthermore, a corresponding increase in the release of tumor necrosis
factor-α was observed in the Ackr2-deﬁcient patella and adjacent
synovial tissue explants, whereas the levels of IL-10 were unchanged
(Figure 1c). Histological analysis revealed a trend toward an increase
in pathological changes in the inﬂamed joints in Ackr2-deﬁcient mice,
but this failed to achieve statistical signiﬁcance (Figure 1d). Thus,
ACKR2 is locally upregulated in response to the development of
inﬂammation in the mouse joint, controls the levels of inﬂammatory
CC chemokines in the diseased tissue and suppresses the clinical
symptoms of arthritis.
Loss of ACKR2 does not alter anti-collagen antibody levels in CIA
or the development of antibody-driven inﬂammatory arthritis
Loss of ACKR2 did not affect the level of subclass-speciﬁc anti-type II
collagen (CII) antibodies produced during CIA (Figure 2a). However,
we thought that the increased clinical disease in Ackr2-deﬁcient mice
in CIA might be the result of an altered innate response in the joint to
these pathogenic antibodies. To investigate this directly, we examined
the impact of Ackr2 deﬁciency on the development of anti-collagen
antibody-induced arthritis. Pathology in this model relies heavily
on innate effector mechanisms involving neutrophils, macrophages,
Fc receptors, complement and inﬂammatory chemokines and
cytokines.29 However, loss of ACKR2 had no impact on the develop-
ment or maintenance of arthritic disease in this model (Figure 2b).
Thus, the enhanced disease observed in Ackr2-deﬁcient mice in the
CIA model was unlikely to be the result of exaggerated responses to
anti-collagen antibodies.
Increased IL-17 production in LNs draining arthritic joints in
Ackr2-deﬁcient mice
Next, we examined whether there was any evidence of altered T-cell
responses in arthritic Ackr2-deﬁcient mice by analyzing inguinal LNs
draining the arthritic hind legs of WT and Ackr2-deﬁcient mice
35 days after the induction of disease. Ackr2 deﬁciency had no impact
on the cellularity of these LNs in resting mice (data not shown), but
more cells were retrieved from the inﬂamed inguinal LNs of arthritic
Ackr2-deﬁcient mice than from WT counterparts (Figure 3a). There
was no difference in the proliferative response of these cells to CII
stimulation (Figure 3b), but, compared with WT, Ackr2-deﬁcient cells
released approximately ﬁvefold more IL-17 into the medium after CII
stimulation (Figure 3c). In contrast, there was no difference in CII-
induced tumor necrosis factor-α or IL-10 production by LN cells
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harvested from WT and Ackr2-deﬁcient mice (Figures 3d and e).
However, Ackr2-deﬁcient cells produced signiﬁcantly more GM-CSF
after stimulation with CII (Figure 3f) and, interestingly, in the CII-
stimulated Ackr2-deﬁcient cultures, the level of IL-17 signiﬁcantly
correlated with GM-CSF abundance (r2= 0.72, P= 0.03; Figure 3g).
Moreover, compared with WT, the inguinal LNs draining the inﬂamed
joints of Ackr2-deﬁcient mice showed a small, but statistically
signiﬁcant, increase in the proportion of CD4+ T cells capable of
producing IL-17 after stimulation in vitro with phorbol 12-myristate
13-acetate/ionomycin, indicative of an increased generation of Th17
cells in these mice (Figure 3h). This bias was restricted to CD4+ IL-17-
producing cells as no signiﬁcant differences were observed in the
proportion of IL-17+ CD8+ or γδ T cells (data not shown and
Supplementary Figure 1). Thus, Ackr2-deﬁcient mice developed an
effective T-cell response to CII, and, by day 35, their CD4+ T-cell
population had a signiﬁcantly greater Th17 component.
ACKR2 suppresses the development of Th17 cells during the
initiation of the arthritogenic immune response
The resistance of Ackr2-deﬁcient mice to EAE was ascribed to a defect
in T-cell priming,26 but our data showed that there was a plentiful
supply of collagen-speciﬁc lymphocytes in arthritic Ackr2-deﬁcient
mice. This suggested that loss of ACKR2 might not suppress the
priming of antigen-speciﬁc T cells in the CIA model. To speciﬁcally
evaluate this, WT and Ackr2-deﬁcient DBA1/j mice were immunized
with CII in complete Freund’s adjuvant and draining LNs were
harvested on day 8, the time point selected in previous work after
immunization with MOG35–55.
26 However, in marked contrast to the
poor T-cell responses reportedly elicited by MOG35–55,
26 proliferation
and IFNγ secretion of antigen-stimulated lymphocytes were not
suppressed in Ackr2-deﬁcient LNs (Figures 4a and b). In fact, and
in line with the data from the arthritic mice (Figure 3), a signiﬁcant
increase in the production of IL-17 was observed after stimulation of
Ackr2-deﬁcient lymphocytes with CII and, strikingly, this cytokine was
not detectably induced when WT lymphocytes were used (Figure 4c).
Thus, loss of ACKR2 does not impair the ability to detect and respond
to antigenic challenge in this model, and it actually enhances the initial
Th17 response.
MOG35–55-induced EAE is not suppressed by the absence of ACKR2
The absence of suppressed T cell priming after immunization with
collagen led us to re-evaluate the role ACKR2 during EAE induction in
C57BL/6J mice. In stark contrast to the previous work,26 we found
that Ackr2 deﬁciency offered no protection against disease after
immunization with MOG35–55 peptide (Figure 5a). We were also
unable to observe a difference in the accumulation of DCs at the site
of immunization in Ackr2-deﬁcient mice 3 days after injection
(Figure 5b), although in the draining LN at this time there was a
Figure 1 ACKR2 regulates chemokine abundance in arthritic joints and suppresses disease severity in CIA. (a) RNA was extracted from the knees of WT
DBA/1j mice with established CIA (day 35) or age- and sex-matched naive littermate control mice (n=6). Quantitative reverse transcriptase-PCR (Q-RT-PCR)
was performed to evaluate the level of Ackr2 expression. Ackr2 gene expression was normalized to GAPDH and the fold change in inﬂamed tissue calculated
relative to naive tissue (set to 1). (b–d) CIA was induced in wild-type littermate control (WT) and Ackr2-deﬁcient (Ackr2− /−) DBA/1j mice with 100 μg of
bovine CII in complete Freund’s adjuvant. (b) Clinical score, with each point representing the pooled mean± s.e.m. scores of three experiments using n=29
mice of each genotype. Signiﬁcance was determined by two-way repeated measures analysis of variance (ANOVA) with Bonferroni post tests. *Po0.05 and
**Po0.01. (c) Knee patella and adjacent synovial tissue were harvested (n=6–8), cultured ex vivo for 4 h and the level of secreted chemokine and
cytokines determined by ELISA. *Po0.05 and **Po0.01 (Mann–Whitney test). (d) Histological scores. Hematoxylin and eosin (H&E)-stained tissue sections
were scored in a blinded manner for hyperplasia, inﬁltration and erosion. Bars show mean± s.d. of 5–6 per group.
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signiﬁcant decrease in the number of CD207+ EPCAM+ migratory
DCs in Ackr2-deﬁcient mice (Figure 5c) that was also evident at day 21
(data not shown). Nonetheless, no differences were detected in
lymphocyte proliferation on day 11 or day 21 when the Ackr2-
deﬁcient and WT inguinal LN cells were stimulated ex vivo with
MOG35–55 (Figure 5d, and data not shown). Importantly, in this
setting Ackr2-deﬁcient cells did not produce more IL-17 than their
WT counterparts (Figure 5e). Thus, although loss of ACKR2 did
reduce the number of migratory DCs in the LN draining the site of
MOG35–55 immunization, it did not hamper the ability of T cells to
respond to antigenic challenge and, in contrast to immunization with
CII protein, there is no evidence of an enhanced Th17 response.
MOG1–125-induced EAE is not suppressed by the absence of ACKR2
but Th17 responses are enhanced
Ackr2 deﬁciency did not affect the Th17 response in the peptide-driven
C57BL/6 model of EAE, but enhanced this response in the DBA1/j
collagen-driven model of CIA. This led us to question the role of
ACKR2 and/or genetic background in protein-driven priming of T-cell
responses. As above, when EAE was induced in WT and Ackr2-
deﬁcient mice on the C57BL/6 or DBA1/j strain using MOG1–125
protein, Ackr2 deﬁciency did not offer any protection against disease
(Figures 6a and b). In fact, there was a small, but statistically
signiﬁcant, increase in the clinical symptoms of disease in Ackr2-
deﬁcient DBA1/j mice 11 days after immunization (Figure 6b),
although histological examination of the brains of these animals failed
to reveal any change in leukocyte inﬁltrate (data not shown). The
severe EAE induced in Ackr2-deﬁcient DBA1/j mice by MOG1–125
meant that, under the terms of our license, animals had to be killed on
day 11. As in the other models, no differences were detected in
lymphocyte proliferation when Ackr2-deﬁcient and WT inguinal LN
cells were stimulated ex vivo with MOG1–125, and IFNγ production
was also unaffected (data not shown), but notably Ackr2-deﬁcient cells
from both C57BL/6 and DBA1/j mice produced signiﬁcantly more
IL-17 than their WT counterparts (Figures 6c and d). In further
experiments, MOG1–125-immunized WT and Ackr2-deﬁcient C57BL/6
mice were treated with pertussis toxin on days 0 and 2 (Supplementary
Figure 2). As before, these animals developed comparable clinical
symptoms and elevated Th17 responses. Thus, loss of ACKR2 does not
suppress the pathogenicity of protein autoantigens (collagen and
MOG1–125) and is consistently associated with enhanced Th17
responses, regardless of genetic background.
Enhanced Th17 responses in Ackr2-deﬁcient mice are not due to
intrinsic T-cell defects
Although there is no evidence that T cells express ACKR2 protein in
mice,9 transcripts encoding ACKR2 can be detected in mouse T cells
activated in culture, and in samples of mouse secondary lymphoid
tissues that have been enriched for T cells.8 It was possible therefore
that Ackr2 expression by T cells played a role in regulating the
generation of Th17 cells. To examine this, we generated chimeric mice
carrying both WT and Ackr2-deﬁcient hematopoietic cells to allow us
to evaluate whether WT and Ackr2-deﬁcient T cells activated in the
same host differed in their ability to generate Th17 cells. These animals
were immunized with MOG1–125 protein, and Th1 and Th17 cells
identiﬁed in the WT and Ackr2-deﬁcient CD4+ T-cell populations in
the inguinal LN by using intracellular cytokine staining to identify
T cells capable of producing IFNγ or IL-17, respectively. Under these
circumstances, there was no difference in the percentage of WT and
Ackr2-deﬁcient T cells that could be classiﬁed as Th1 or Th17 cells
(Figures 6e and f). Thus, ACKR2 in T cells does not detectably
inﬂuence their ability to develop into Th17 cells.
Enhanced Th17 responses in Ackr2-deﬁcient mice are associated
with increased numbers of GM-CSF+ B cells in draining LN
ACKR2 is expressed by IBCs, including rare B1 cells in LN, and the B1
B-cell compartment is perturbed in resting Ackr2-deﬁcient mice.9 B1a
B cells have been shown to give rise to a population of cells in the
spleen during inﬂammation that are a dominant source of GM-CSF.10
GM-CSF, via IL-6 and IL-23, enhances Th17 cell development and
survival.28 Thus, we considered whether during the initiation of an
immune response, GM-CSF+ B cells were present in draining LN, and
whether their abundance was affected by Ackr2 deﬁciency. LNs were
harvested 8 days after immunization of WT and Ackr2-deﬁcient
C57BL/6 mice with MOG35–55 or MOG 1–125, and GM-CSF expression
assessed by intracellular cytokine staining (Figure 7, and data not
shown). Small numbers of GM-CSF+ B cells were detected in the LNs
of WT mice, and the number retrieved was similar irrespective of
whether they had been immunized with peptide (66 107± 27 981 GM-
CSF+ B cells; mean± s.d.) or protein (79 406± 18 994 GM-CSF+ B
cells; mean± s.d.). Interestingly, however, draining LNs from Ackr2-
deﬁcient mice immunized with MOG1–125 protein contained signiﬁ-
cantly more GM-CSF+ B cells than their WT counterparts, whereas no
increase was observed when MOG35–55 peptide was used. No
differences were detected in the levels of GM-CSF+ non-B-cell
populations in Ackr2-deﬁcient and WT counterparts (Figure 7).
Surface immunophenotyping revealed that these cells, whether WT
or Ackr2 deﬁcient, were mostly CD138− CD43− IgMhi IgDhi, although
approximately a quarter had much lower levels of surface IgM (data
not shown). Thus, enhanced Th17 responses of Ackr2-deﬁcient
mice are associated with an increase in the number of B cells making
Figure 2 Ackr2 deﬁciency has no impact on the generation of anti-collagen
antibodies in CIA and or on antibody-induced arthritis. (a) Serum levels of
anti-collagen mouse IgG1 and IgG2a in arthritic wild-type littermate control
(WT) and Ackr2-deﬁcient (Ackr2− /−) DBA/1j mice (n=16) at 35 days after
the ﬁrst collagen immunization. (b) Collagen antibody-induced arthritis
(CAIA) was induced in wild-type (WT) and Ackr2-deﬁcient (Ackr2− /−) DBA/1j
mice with each animal assessed every 1 to 2 days for clinical symptoms of
arthritis. Each point represents the mean± s.e.m. scores of n=5 mice.
Signiﬁcance was determined by two-way repeated measures analysis of
variance (ANOVA).
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GM-CSF, a cytokine that controls the development and survival of
Th17 cells.
DISCUSSION
In the models we have examined, and using mice on two different
genetic backgrounds, we ﬁnd that deletion of Ackr2 does not suppress
T-cell priming or provide protection against autoimmunity. It can
however enhance Th17 responses and the abundance of GM-CSF+ B
cells in LNs after immunization with protein, but not peptide,
autoantigen.
The responses that we observed in WT and Ackr2-deﬁcient C57BL/
6j mice after immunization with MOG35–55 clearly differ from those
reported by Liu et al.,26 even though very similar immunization
strategies were used. In their study, the reduced clinical and
histopathological signs of disease seen in Ackr2-deﬁcient mice from
day 14 after immunization with MOG35–55 were attributed to
dysregulated inﬂammation at the site of immunization causing
defective DC migration from the skin.26 We have found that Ackr2
deﬁciency can lead to ‘lymphatic congestion’ and the impaired
movement of antigen-presenting cells from the skin,27 and shown
here that DC migration to draining LNs is attenuated in Ackr2-
deﬁcient mice after immunization with MOG35–55. Thus, ACKR2 does
allow optimal DC trafﬁcking to LN from inﬂamed skin. Where our
studies differ is in the impact of Ackr2 deﬁciency on T-cell priming
and disease course. Liu et al.26 reported that LN cells draining the site
of immunization in Ackr2-deﬁcient mice were virtually unable to
proliferate after restimulation with antigen ex vivo, in stark contrast to
the strong responses seen when LN cells from immunized WT mice
were used. We saw robust proliferative responses in Ackr2-deﬁcient
mice after immunization with MOG35–55 (or, indeed, collagen or
MOG1–125) and these responses were no weaker than those seen in
WT controls. Although EAE was successfully induced in both studies,
we failed to see the divergence in the clinical scores of WT and Ackr2-
deﬁcient C57BL/6j mice 14 days after immunization with MOG35–55
that was reported in the previous work. This was also the case after
immunization of WT and Ackr2-deﬁcient C57BL/6j mice with MOG1–
125. There was in fact a small increase in EAE score when Ackr2-
deﬁcient mice on a DBA/1j background were compared with WT
DBA/1j mice, and Ackr2-deﬁcient DBA/1j mice also developed worse
arthritis than WT animals during CIA. We have yet to resolve the
Figure 3 Arthritic Ackr2-deﬁcient mice have enlarged draining LNs capable of greater collagen-induced IL-17 production. Draining LNs (n=6–10) were
collected from wild-type (WT) and Ackr2-deﬁcient (Ackr2− /−) DBA/1j mice 35 days after collagen immunization. (a) Number of LN cells retrieved.
(b–g) Draining LN cells (3×105 cells per well) were stimulated ex vivo with or without antigen (CII, 60 μgml−1). (b) Ag-induced proliferation (that is, CII
minus medium alone), as determined by incorporation of tritiated thymidine ([H3]-TdR). (c–f) Concentration of IL-17, tumor necrosis factor-α (TNFα), IL-10
and GM-CSF in the medium after stimulation with antigen (CII) or medium alone (m). Signiﬁcance was determined by one-way analysis of variance (ANOVA)
with Bonferroni multiple comparison post tests. *Po0.05 and **Po0.01. (g) Correlation between the concentration of GM-CSF and IL-17. Signiﬁcance was
determined by Spearman’s rho test. (h) Representative results from IL-17 intracellular ﬂow cytometry and a bar graph showing the percentage of LN cells
that were CD4+IL17+ cells. A repeat experiment yielded similar results. Signiﬁcance was determined by t-test. *Po0.05.
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differences between our study and those of Liu et al.,26 but our
ﬁndings clearly challenge the notion that ACKR2 facilitates the
development of pathogenic T cells in mouse models of autoimmune
disease.
Ackr2 expression was upregulated in the knees or central nervous
system of DBA1/j mice with CIA or EAE, respectively (Figure 1, and
data not shown), perhaps in an effort to counteract ongoing
inﬂammation. The source of this Ackr2 is not clear and there are no
effective anti-ACKR2 antibodies available with which to identify and
localize ACKR2-expressing cells by immunohistochemistry in mouse
tissues. However, as ACKR2 is found in subsets of leukocytes,
lymphatic endothelial cells and epithelial cells in resting and inﬂamed
human tissues, including those affected by autoimmune disease,4,8,30,31
it seems likely that these cell types are responsible for Ackr2 expression
in inﬂamed tissues in mice. However, it remains unclear whether the
enhanced Ackr2 expression seen during autoimmune inﬂammation is
either because of its presence on inﬁltrating leukocytes or its induction
on resident cells by signals that are still to be deﬁned. Synovial explants
from arthritic Ackr2-deﬁcient DBA1/j mice released more ACKR2-
binding chemokine (CCL2, 3 and 4) than WT counterparts, whereas
levels of the non-ACKR2 ligand CXCL10 were unaffected. These data
suggest that loss of ACKR2-mediated chemokine scavenging in the
target tissue might contribute to the enhanced clinical symptoms seen
in Ackr2-deﬁcient DBA1/j mice in CIA. However, the enhanced Th17
responses alone could be responsible, and this is supported by the fact
that clinical symptoms of disease are unaffected by Ackr2 deﬁciency in
models that exclusively examine the effector arm of disease develop-
ment (such as, anti-collagen antibody-induced arthritis in DBA1/j
Figure 4 Ackr2 deﬁciency leads to an increased Th17 response during the
induction of arthritis. At 8 days after challenge with CII, draining LNs were
harvested from WT littermate control (WT) and Ackr2-deﬁcient (Ackr2− /−)
DBA/1j mice (n=5) and the recall immune response evaluated. Single-cell
suspensions of LN cells (3×105 cells per well) were stimulated with CII
(60 μgml−1) or medium alone and assessed for (a) speciﬁc proliferation (that
is, proliferation after CII stimulation minus proliferation in medium alone) or
(b, c) the levels of IFNγ and IL-17 in the medium. **Po0.01 by Kruskal–
Wallis test with Dunn’s multiple comparison post test. A repeat experiment
yielded similar results.
Figure 5 Ackr2 deﬁciency does not impair disease severity in the MOG35–55 peptide-induced model of EAE or result in increased IL-17 production. EAE
was induced in WT littermate control (WT) and Ackr2-deﬁcient C57BL/6 mice (Ackr2− /−) by immunization with MOG35–55 (100 μg) in complete Freund’s
adjuvant (4mgml−1 Mycobacterium tuberculosis H37RA) and treatment on days 0 and 2 with 200 ng of pertussis toxin (PTX). (a) All animals
were assessed daily for the development of clinical symptoms of disease. Each point represents the mean± s.e.m. scores for n=5 mice. A repeat
experiment yielded similar results. (b) Injection site skin was harvested on day 3 and the number of CD207+ DCs in 10 high-power ﬁelds (HPFs) per mouse
determined. (c–e) Draining LNs were harvested on day 3 or day 11 and single-cell suspensions were evaluated for (c) the absolute number of
CD207+EPCAM+ DCs (day 3) or (d, e) 3 ×105 cells per well stimulated with MOG35–55 (30 μgml−1) (day 11) and assessed for (d) speciﬁc proliferation
(proliferation after MOG35–55 stimulation minus proliferation in medium alone) or (e) the level of IL-17 in the medium. Signiﬁcance was determined by
t-test. *Po0.05.
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mice; EAE in C57BL/6J mice driven by transfer of MOG35–55-primed
T cells26). Thus, it is unlikely that ACKR2 in the joint or central
nervous system plays any signiﬁcant role in regulating the inﬂamma-
tion that develops in these tissues in the models that we have used.
The amount of ACKR2 expressed at these sites may be insufﬁcient to
scavenge enough chemokine to exert any inhibitory effect on disease
progression in the presence of autoreactive T cells and autoantibodies,
and joints and brain are relatively poor sources of ACKR2 compared
with skin, lung, gut and placenta where the effects of Ackr2 deﬁciency
are most apparent.2,5,6,16–21
One consistent feature of our study was the enhanced Th17
responses seen in Ackr2-deﬁcient mice after immunization with
protein (collagen or MOG1–125) but not peptide (MOG35–55). The
data from the analysis of mixed bone marrow chimeras, in which WT
and Ackr2-deﬁcient T cells developed equally well into Th17 cells in
response to protein antigen, suggest that this was not due to an
intrinsic T-cell defect arising from loss of Ackr2. It may instead be due
to differences in antigen presentation, and interestingly, peptide and
protein can be presented by distinct antigen-presenting cells.32,33 In
general terms, peptides are most efﬁciently presented to naive T cells
by DCs, but proteins can be processed and presented by other cells,
most notably B cells. Indeed, a dependence on B-cell presentation for
T-cell priming has been demonstrated in protein-induced models of
both arthritis and EAE.34,35 Moreover, B-cell depletion leads to
diametrically opposed outcomes in the two modes of immunization:
exacerbating peptide-driven EAE but suppressing protein-induced
disease.35 In the protein model, high titers of pathogenic MOG-
speciﬁc antibody are generated and B cells are capable of efﬁciently
priming encephalogenic Th1 and Th17 cells. In the peptide model,
MOG-speciﬁc antibody is less important, DCs are thought to dominate
T-cell priming and IL-10-producing regulatory B cells can suppress
disease.36 Thus, in Ackr2-deﬁcient mice immunized with MOG1–125 or
collagen, it appears likely that B cell-mediated T-cell priming over-
comes any ‘lymphatic congestion’ or reduction in DC-mediated T-cell
priming that might conceivably be occurring in these animals.
An increased dependence on B cells for T-cell priming in Ackr2-
deﬁcient mice might be responsible for the increase in IL-17-
producing cells that we see in LNs after their immunization with
collagen or MOG1–125 protein. In this regard, it is intriguing that IBC
(that is, marginal zone and B1 B cells) are the principal leukocytes that
Figure 6 Ackr2 deﬁciency leads to increased IL-17 production after the induction of EAE in C57BL/6 and DBA/1j mice, and has minimal effect on disease
severity. (a–d) EAE was induced in WT littermate control (WT) and Ackr2-deﬁcient (Ackr2− /−) C57BL/6 (a, c) or DBA/1j (b, d) mice by immunization with
MOG1–125 protein (50 μg in 3mgml−1 Mycobacterium tuberculosis H37RA CFA). (a, b) Animals evaluated daily for clinical symptoms of disease. In (a), each
point represents the means± s.e.m. (n=5 mice per genotype). A repeat experiment generated a similar result. In (b), the pooled mean± s.e.m. scores of two
experiments are shown (n=10–11 mice per genotype). Signiﬁcance was determined by two-way repeated measures analysis of variance (ANOVA) with
Bonferroni post tests. ***Po0.001. (c, d) At 21 (n=5) (c) or 11 days (n=10–11) (d) after immunization, 3×105 cells per well from LNs draining the site
of immunization were stimulated ex vivo with MOG1–125 (60 μgml−1) or medium alone and the concentration of IL-17 in the medium was determined.
*Po0.05 by Mann–Whitney test. ND=not detected. (e, f) Mixed bone marrow chimeric mice (WT:Ackr2− /−) were immunized with MOG1–125 protein (50 μg
in 3mgml−1 Mycobacterium tuberculosis H37RA CFA), draining inguinal LNs were harvested on day 15 and the number of CD4+TCRβ+CD45.1+ (WT) or
CD4+TCRβ+CD45.1− (Ackr2− /−) IL-17A+ and IFNγ+ T cells determined. (e) Bar graphs showing the percentage of CD4+TCRβ+ cells that were IL17+ or IFNγ+.
(f) Representative ﬂow cytometry plots pregated on live singlet CD4+TCRβ+CD45.1+ (WT) or CD4+TCRβ+CD45.1− (Ackr2− /−).
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express ACKR2 in mice.9 These cells exhibit a number of properties
that might contribute to the generation of Th17 responses. For
example, compared with follicular B cells, antigen-loaded IBCs are
particularly adept at priming naive T cells,37 and B1 B cells are known
to bias T-cell differentiation toward a Th17 phenotype ex vivo.38
Moreover, B1 B cells can give rise to GM-CSF+ B cells in the
spleen,10 and during inﬂammation these cells appear to be a dominant
leukocytic source of this cytokine that is known to enhance Th17 cell
development and survival.28 Our work now demonstrates that GM-
CSF+ B cells are present in LNs draining immunized skin, and their
abundance is regulated by ACKR2 after immunization with protein
autoantigens. The precise identity and origin of these cells remains
uncertain, and their surface immunophenotype is clearly distinct from
the GM-CSF+ B cells that can be generated in the spleen to provide
protection against microbial sepsis that express CD43 and CD138,
among other markers.10 Nonetheless, we speculate that GM-CSF+ B
cells contribute, at least in part, to the enhanced Th17 responses seen
in Ackr2-deﬁcient animals and experiments are underway to explore
this possibility. Mechanistically, their increased abundance in inﬂamed
Ackr2-deﬁcient LN may be linked to cell-autonomous changes in the
migratory properties of these cells, or their precursors. Ackr2
deﬁciency enhances the migration of B1 B cells toward the non-
ACKR2 ligand CXCL13,9 the principal chemokine involved in the
localization of B cells, including IBCs.22 Through its receptor CXCR5,
it recruits B cells into follicles in secondary lymphoid tissues and
regulates their intrafollicular motility. It is conceivable that enhanced
CXCL13 responsiveness alters the recruitment or positioning of
certain subsets of B cells in Ackr2-deﬁcient mice before or during
inﬂammation, and that this favors the development of GM-CSF+ B
cells. These possibilities are currently being addressed in our
laboratory.
In conclusion, ACKR2 can regulate T-cell priming and GM-CSF-
producing B cells during the induction of arthritic and neuropathic
autoimmunity in mice, and its deletion leads to subtle changes in the
development of disease. The precise nature of this regulation depends
on whether peptide or protein antigen is used to induce the disease,
clearly demonstrating the importance of using multiple models when
assessing the role of speciﬁc genes in autoimmunity. Given the
regulatory role of ACKR2 during inﬂammation and T-cell priming,
it is important that studies are now undertaken to further investigate
the expression and regulation of ACKR2 in the inﬂamed tissues and
draining LNs of patients with autoimmune disease, and it remains to
be seen whether ACKR2-mediated chemokine scavenging can inﬂu-
ence disease progression in humans. A greater understanding of these
aspects of ACKR2 biology could potentially lead to the development of
new treatments in which the artiﬁcial elevation of ACKR2 in
chronically inﬂamed tissues could be used to broadly suppress
chemokine-driven inﬂammation.
METHODS
Mice
Ackr2-deﬁcient mice (DBA1/j (F10) and C57BL/6J (F11)) and WT counterparts
were housed under speciﬁc pathogen-free conditions at Glasgow University’s
Central Research Facility. Animal studies were approved by the University of
Glasgow Ethical Review Process and licensed by the UK Home Ofﬁce.
Induction and assessment of arthritis
CIA was induced in DBA/1j mice with 100 μg of bovine CII emulsiﬁed in
complete Freund’s adjuvant (MD Biosciences, Zürich, Switzerland) at the base
of the tail on day 0, and boosted on day 21 with an intraperitoneal injection of
CII in phosphate-buffered saline (PBS), as previously described.39 Collagen
antibody-induced arthritis was induced by intravenous injection of 2mg of
collagen antibody cocktail (Chondrex, Redmond, WA, USA). After 3 days,
lipopolysaccharide (50 μg per mouse, Chondrex) was injected intraperitoneally.
Mice were scored by a ‘genotype-blinded’ observer for clinical signs of disease,
as previously described.39 Hind paws were histologically scored for inﬂamma-
tion and joint damage, as previously described.40 In brief, 0=healthy, 1=mild,
2=moderate and 3= severe. A genotype-blinded observer scored three sections
per knee and the mean score per group was calculated.
Figure 7 Ackr2 deﬁciency leads to increased numbers of GM-CSF+ B cells in draining LNs after immunization with MOG1–125 protein. EAE was induced in
WT littermate control (WT) and Ackr2-deﬁcient (Ackr2− /−) C57BL/6 mice (n=4) by immunization with MOG1–125 protein (50 μg in 3mgml−1 Mycobacterium
tuberculosis H37RA CFA), draining LNs harvested on day 8, and the number of GM-CSF+ CD19+ B cells determined. (a) Representative ﬂow cytometry plots
that were pregated on live IgD+IgM+ singlets (top panels) and live IgD−IgM−CD19− singlets (bottom panels), and the percentage of GM-CSF+ CD19+ B cells
and GM-CSF+ CD19− non-B cells respectively are shown. (b) Box and whisker plots, where the boxes represent the 25th to 75th percentiles, the lines within
the boxes represent the median and the lines outside the boxes represent the 5th and 95th percentiles, show the absolute number of GM-CSF+ B cells (top
plot) and GM-CSF+ non-B cells (bottom plot) in the draining LNs. The dotted line represents the isotype control level. A repeat experiment yielded similar
results. *Po0.05 by Mann–Whitney test.
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Quantitative PCR
RNA was extracted using RNeasy columns with DNAse treatment (Qiagen,
Manchester, UK), complementary DNA generated (AfﬁnityScript (Agilent,
Santa Clara, CA, USA)) and quantitative PCR done using Ackr2-speciﬁc
Taqman assay (mm0044555_m1) (Life Technologies, Paisley, UK) on a Prism
7900HT (Life Technologies). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)-speciﬁc probes were used to normalize Ackr2 expression. Analysis
used the relative quantitation ΔΔ− 2 CT method to give the relative quantiﬁca-
tion (fold change) value, with naive tissue as calibrators set to 1.
Synovial tissue explants
Patella and adjacent synovium were dissected and immediately incubated in
complete RPMI for 4 h at 37 °C. The supernatant was harvested and assayed for
chemokines, as described below.
Restimulation of LN cells
Inguinal LN cells were harvested and single-cell suspensions prepared by
enzymatic digestion using 1mgml− 1 collagenase D (Roche, Burgess Hill, UK)
in Hanks’ balanced salt solution without calcium and magnesium. Cells were
cultured in triplicate in 96-well round-bottomed plates at 3× 105 cells per well
in complete Dulbecco’s modiﬁed Eagle’s medium. Cells were restimulated with
medium, 60 μgml− 1 of bovine tracheal cartilage (Sigma-Aldrich, Gillingham,
UK) (in CIA model) or 30 μgml− 1 of the MOG35–55 peptide or MOG1–125
protein (in EAE model). Proliferation was analyzed at 88 h by [3H]Thymidine
(GE Healthcare, Little Chalfont, UK) incorporation during the last 16 h of
culture.
Luminex and enzyme-linked immunosorbent assay (ELISA)
Cytokines, chemokines and anti-collagen antibody (Ab) levels were quantiﬁed by
Luminex (Life Technologies) or ELISA using appropriately diluted sera or culture
supernatants. Reagents for the quantiﬁcation of mouse chemokines, IFNγ, IL-17
and tumor necrosis factor-α were from Biosource (Life Technologies), and assays
were performed according to the manufacturer’s instructions. Anti-collagen Ab
titers of individual sera were evaluated using ELISA-grade collagen (Chondrex)
and detected with horseradish peroxidase-conjugated anti-mouse IgG1 or IgG2a
(Southern Biotech, Birmingham, AL, USA). Total IgG was determined using an
unlabeled anti-mouse IgG capture Ab and detected with horseradish peroxidase-
conjugated anti-mouse IgG1 or IgG2a. Antibody ELISAs were developed using o-
phenylenediamine dihydrochloride substrate (Sigma-Aldrich).
Flow cytometry
LN cells were harvested and single-cell suspensions prepared by enzymatic
digestion using 1mgml− 1 collagenase D (Roche) in Hanks’ balanced salt
solution without calcium and magnesium. These cells were resuspended in
FACS buffer (PBS, 1% fetal calf serum, 0.02% sodium azide and 5mM EDTA).
1–3×106 cells per well of a 96-well round-bottomed plate were incubated with
50 μl of a 5 μgml− 1 solution of FC block (BD Biosciences, Oxford, UK) for
15min on ice, washed twice with FACS buffer and stained with ﬂuorescently
labeled Abs (various concentrations) and Viaprobe (BD Biosciences) or ﬁxable
viability dye eFluor 506 or 780 (eBioscience, Hatﬁeld, UK) (to exclude dead
cells). FACS analysis of blood samples was performed similarly with an additional
blood cell lysis step performed using ammonium chloride solution (Stemcell
Technologies, Grenoble, France) according to the manufacturer’s instructions
immediately before staining. Abs against the following surface markers were used,
with clone names and suppliers given in parentheses: TCRβ (H57-597), CD3
(145-2C11), CD4 (H129.19), CD11b (M1/70), GMCSF (MP1-22E9), IL-17
(TC11-18H10), IFNγ (XMG1.2) (BD Biosciences), CD5 (53-7.3), CD11c (N418),
CD207 (Langerin) (EbioL31), MHCII (I-A/I-E) (M5/114.15.2), (eBioscience),
CD19 (6D5), EpCAM-1 (2E7) (Biolegend, London, UK) with a variety of
conjugated ﬂuorochromes); appropriate isotype controls were purchased from
BD Biosciences or eBioscience. For intracellular cytokine staining the BD
Biosciences Cytoﬁx/Cytoperm Fixation/Permeabilization Solution Kit with BD
GolgiPlug was used according to the manufacturer’s instructions. Brieﬂy, for
assessment of cytokine secretion in T cells, 1× 106 isolated LN cells were cultured
for 5 h at 37 °C in complete RPMI in the presence of 500 ngml− 1 of ionomycin,
50 ngml− 1 of phorbol 12-myristate 13-acetate and Golgistop. To detect GM-CSF
production by B cells, LN cells were cultured as described above but in the
absence of phorbol 12-myristate 13-acetate and ionomycin. Cultured cells were
subsequently stained for surface antigens as above and dead cells were excluded
using ethidium monoazide or ﬁxable viability dye eFluor 506 or 780
(eBioscience). Cells were ﬁxed and permeabilized, and stained for intracellular
cytokines. The Cytoﬁx/Cytoperm Fixation/Permeabilization Solution Kit was
used to stain for CD207. In this case the 5-h culture step was excluded; otherwise
the methodology remained the same. Positive populations were deﬁned on the
basis of size (to exclude doublet populations), viability (that is, viability dye
negative) and ‘ﬂuorescence minus one’ isotype controls. Data were analyzed
using FlowJo software (Treestar Inc., Ashland, OR, USA).
Induction and assessment of EAE
EAE was induced in DBA/1j and C57BL/6 mice with either 50 μg of
recombinant rat MOG1–125,
41 emulsiﬁed in incomplete Freund’s adjuvant
(Sigma-Aldrich) supplemented with 3mgml− 1 of heat-inactivated Mycobacter-
ium tuberculosis H37RA (Difco Laboratories, Oxford, UK), or in C57BL/6 mice
with 100 μg of MOG35–55 peptide (AnaSpec, Fremont, CA, USA) emulsiﬁed in
incomplete Freund’s adjuvant (Sigma-Aldrich) supplemented with 4mgml− 1
of heat-inactivated Mycobacterium tuberculosis H37RA (Difco Laboratories).
The emulsion was injected intradermally at the base of the tail. In some
experiments (as indicated in the ﬁgure legends), animals were treated with
200 ng of pertussis toxin (Enzo Life Sciences, Farmingdale, NY, USA) via
intraperitoneal injection on days 0 and 2. Clinical assessment was performed
daily by an observer ‘blinded’ to mouse genotype and according to the
following criteria: 0, no disease; 1, decreased tail tone; 2, abnormal gait (ataxia)
and/or impaired righting reﬂex (hind limb weakness or partial paralysis); 3,
partial hind limb paralysis; 4, complete hind limb paralysis; 5, hind limb
paralysis with partial forelimb paralysis; and 6, moribund or dead.
Generation of mixed chimeric mice
Mice with a mixed WT and ACKR2-deﬁcient hematopoietic compartment were
generated using the mixed bone marrow chimera system. WT (CD45.1) mice
were irradiated with 5.5 Gy followed by 2 h of rest period and then a second
dose of 5.5 Gy. The irradiated mice were reconstituted immediately with a
mixed inoculum of bone marrow (50% CD45.1/.2 WT and 50% CD45.2
ACKR2-deﬁcient). The hematopoietic compartment was left for 2 months to
repopulate. Chimerism was conﬁrmed by FACS analysis of blood retrieved
from the lateral tail vein as described previously using antibodies against mouse
CD45.1 (A20) and CD45.2 (104) (eBioscience).
Immunohistochemistry
Skin was harvested from the injection site immediately proximal to the base of
the tail as well as uninvolved skin from the back. The skin samples were
embedded in Cryomatrix (Thermo Fisher Scientiﬁc, Waltham, MA, USA) and
frozen in a bath of isopentane chilled with dry ice. Then, 8 μm frozen tissue
sections were cut on a Shandon Crotome FSE (Thermo Fisher Scientiﬁc) and
stored at − 80 °C until required. Tissue sections were ﬁxed in acetone at − 20 °C
for 20min. Unless stated otherwise all subsequent steps were performed at
room temperature. Tissue sections were rehydrated with PBS for 5min and
blocked with 10% normal goat serum and 3% bovine serum albumin fraction
V (Sigma-Aldrich) for 1 h. Sections were stained with unlabeled 5 μgml− 1
CD207 (Langerin) (EbioL31) overnight at 4 °C. The sections were then washed
twice for 5 min with PBS Tween 0.05% and once for 5min with PBS alone
before staining with 10 μgml− 1 goat anti-rat IgG H+L Alexa Fluor 647 (Life
Technologies). Wash steps were repeated as previous. Finally, sections were
stained with 0.2 μg ml− 1 DAPI (Life Technologies) solution in PBS for 30min
before mounting using Vectashield (Vector Laboratories, Peterborough, UK).
Images were taken on a Zeiss imager M2 microscope and Axiovision 4.8
software (Jena, Germany). The numbers of CD207-positive cells per 10 high-
power ﬁelds per sample was determined.
Statistical analysis
GraphPad Prism (La Jolla, CA, USA) was used for all statistical analyses using
(as appropriate and as indicated in the ﬁgure legends) t-test; Mann–Whitney
test; Kruskal–Wallis test with Dunn’s multiple comparison post test; one-way
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analysis of variance with Bonferroni’s multiple comparison post tests; or two-
way analysis of variance with repeated measures. To determine correlations,
Spearman’s rho test was used. Data are presented as mean± s.d., except for
clinical scores that are mean± s.e.m. Pp0.05 was considered statistically
signiﬁcant and all tests were two sided.
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